- Home
- EYPT vs NBR Comparison
EYPT vs NBR Comparison
Compare EYPT & NBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | NBR |
|---|---|---|
| Founded | 1987 | 1952 |
| Country | United States | Bermuda |
| Employees | N/A | 13900 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Oil & Gas Production |
| Sector | Industrials | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | EYPT | NBR |
|---|---|---|
| Price | $14.05 | $85.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | $31.80 | ★ $67.29 |
| AVG Volume (30 Days) | ★ 920.5K | 315.2K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $3.34 |
| Revenue Next Year | $863.07 | $4.35 |
| P/E Ratio | ★ N/A | $4.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.70 | $23.27 |
| 52 Week High | $19.11 | $92.38 |
Technical Indicators
Market Signals| Indicator | EYPT | NBR |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 58.68 |
| Support Level | $11.74 | $73.86 |
| Resistance Level | $14.54 | $92.38 |
| Average True Range (ATR) | 0.72 | 4.61 |
| MACD | 0.21 | -0.49 |
| Stochastic Oscillator | 94.57 | 52.96 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.